CPI-0610 联合和不联合 Ruxolitinib 治疗骨髓纤维化患者的 2 期研究
BET 蛋白小分子抑制剂 CPI-0610 的 1/2 期研究:第 1 期(CPI-0610 在血液系统恶性肿瘤患者中的剂量递增)和第 2 期(CPI-0610 在患者中使用和不使用 Ruxolitinib 的剂量扩展)伴有骨髓纤维化和原发性血小板减少症)
第 1 阶段部分(完成):pelabresib 在既往治疗过的急性白血病、骨髓增生异常综合征、骨髓增生异常/骨髓增生性肿瘤和骨髓纤维化患者中的开放标签、顺序剂量递增研究。
第 2 阶段部分:在骨髓纤维化患者中使用和不使用 Ruxolitinib 的 CPI-0610 的开放标签研究。
CPI-0610 是溴结构域和额外末端 (BET) 蛋白的小分子抑制剂。
研究概览
地位
条件
干预/治疗
研究类型
注册 (实际的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
Alberta
-
Edmonton、Alberta、加拿大、T6G 2G3
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、V6Z 2A5
- St. Paul's Hospital
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8V 5C2
- Juravinski Cancer Centre
-
Toronto、Ontario、加拿大、M5G 2M9
- Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal、Quebec、加拿大、H3T 1E2
- Jewish General Hospital
-
-
-
-
North Rhine-Westphalia
-
Bonn、North Rhine-Westphalia、德国、53127
- Universitatsklinikum Bonn
-
-
Saxony
-
Leipzig、Saxony、德国、04103
- Universitätsklinikum Leipzig AöR
-
-
-
-
-
Florence、意大利、50134
- Azienda Ospedaliero-Universitaria Careggi
-
Novara、意大利、28100
- AOU Maggiore della Carita
-
-
Emilia-Romagna
-
Bologna、Emilia-Romagna、意大利、40138
- Institue of Hematology "L. and A. Seràgnoli"
-
Rimini、Emilia-Romagna、意大利、47923
- Servizio Sanitario Regionale Emilia-Romagna - Azienda Unita Sanitaria Locale (AUSL) di Rimini - Ospedale Infermi di Rimini
-
-
Liguria
-
Genoa、Liguria、意大利、16132
- AOU S.Martino, IRCCS, IST-Istituto Nazionale Ricerca Sul Can
-
-
Lombardy
-
Milan、Lombardy、意大利、20122
- Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda
-
Pavia、Lombardy、意大利、27100
- Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi
-
Varese、Lombardy、意大利、21100
- Ospedale di Circolo, PO Varese, AO Ospedale di Circolo e Fon
-
-
-
-
-
Antwerp、比利时、2060
- ZNA Stuyvenberg Antwerpen
-
-
Viaams Braban
-
Leuven、Viaams Braban、比利时、3000
- UZ Leuven - Campus Gasthuisberg
-
-
West-Vlaanderen
-
Bruges、West-Vlaanderen、比利时、8000
- AZ Sint-Jan Burgge-Oostende AV- Campus Sint-Jan
-
-
-
-
-
Paris、法国、75010
- CHU - Hopital Saint Louis - Centre D'Investigations Clinique
-
-
Gard
-
Nîmes、Gard、法国、30029
- Institut de cancérologie du Gard - Hematologie clinique
-
-
Haute-Garonne
-
Toulouse、Haute-Garonne、法国、31059
- CHRU de Lille - Hopital Claude Huriez
-
-
Hauts-de-France
-
Lille、Hauts-de-France、法国、59037
- CHRU de Lille - Hôpital Claude Huriez - Maladies du Sang
-
-
Île-de-France Region
-
Villejuif、Île-de-France Region、法国、94805
- Institut Gustave Roussy
-
-
-
-
Masovian Voivodeship
-
Warsaw、Masovian Voivodeship、波兰、02-776
- Instytut Hematologii I Transfuzjologii W Warszawie
-
-
Pomeranian Voivodeship
-
Gdansk、Pomeranian Voivodeship、波兰、80-952
- Uniwersyteckie Centrum Kliniczne
-
-
-
-
Arizona
-
Phoenix、Arizona、美国、85054
- Mayo Clinic Arizona
-
-
California
-
Los Angeles、California、美国、90095
- UCLA Medical Center
-
-
Florida
-
Jacksonville、Florida、美国、32224
- Mayo Clinic Jacksonville
-
-
Illinois
-
Chicago、Illinois、美国、60611
- Northwestern University - Lurie Comprehensive Cancer Center
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- Massachusetts General Hospital Cancer Center
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- University of Michigan Medical Center
-
-
Missouri
-
St Louis、Missouri、美国、63110
- Washington University School of Medicne Neuromuscular Division Department of Neurology Research
-
-
New York
-
New York、New York、美国、10029
- Icahn School of Medicine at Mount Sinai
-
New York、New York、美国、10021
- Memorial Sloan Kettering Cancer Center
-
New York、New York、美国、10065
- Weill Medical College and New York Presbyterian Hospital
-
-
Texas
-
Houston、Texas、美国、77030
- The University of Texas MD Anderson Cancer Center
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- Froedtert & Medical College of Wisconsin
-
-
-
-
-
Belfast、英国、BT9 7AB
- Belfast City Hospital
-
Cambridge、英国、CB2 0QQ
- University of Cambridge
-
Cardiff、英国、CF14 4XW
- University Hospital of Wales
-
Glasgow、英国、G12 0YN
- Beatson West of Scotland Cancer Centre
-
London、英国、NW1 2PG
- University College London Hospital's NHS foundation Trust
-
London、英国、SE1 9RT
- Guys and St Thomas' Hospital - Haematology
-
Manchester、英国、M20 4BX
- The Christie Hospital
-
-
Oxford
-
Headington、Oxford、英国、OX3 7LE
- Oxford University Hospitals
-
-
-
-
Limburg
-
Maastricht、Limburg、荷兰、6229 HX
- Maastricht University Medical Center
-
-
North Holland
-
Amsterdam、North Holland、荷兰、1081 HV
- VUmcResearch B.V.
-
-
South Holland
-
Rotterdam、South Holland、荷兰、3015 AA
- Erasmus Universitair Medisch Centrum Rotterdam
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
描述
纳入标准:
第二阶段部分:符合以下所有标准的确诊为 MF 的患者:
- ANC ≥ 1 x 10^9/L 无粒细胞生长因子辅助
- 外周血母细胞计数
- ECOG体能状态≤2。
- 充分的血液学、肾脏、肝脏和凝血实验室评估
- 之前未使用 BET 抑制剂治疗
- 在执行任何与研究相关的程序之前,患者必须提供书面知情同意书才能参与本研究。
对于第 1 组和第 2 组,应考虑以下标准:
- 符合以下所有标准的 MF 确诊患者
- 动态国际预后评分系统 (DIPSS) 风险类别为 2 级或更高
- 队列 1B 和 2B 的 MRI 或 CT 脾脏体积≥ 450 cm^3 或 RBC 输血依赖(定义为在入组前 12 周内每月平均输注 ≥ 2 个单位的 RBC(总共输注超过 6 次 RBC)对于队列 1A 和 2A)
- 使用骨髓纤维化症状评估表版本 4.0 (MFSAF v4.0) 至少可测量 2 种症状(评分 ≥ 1)
- 血小板计数 ≥ 75 x 10^9/L 至少 14 天没有血小板生成因子或输血的帮助
- 手臂(手臂 1):以前接受过 JAK 抑制剂治疗并且对 JAK 抑制剂不耐受、耐药、难治或失去反应;在研究药物开始前 2 周内未接受 JAK 抑制剂,或不符合接受 JAK 抑制剂治疗的资格
- 组合组(第 2 组):必须已接受单一药物 ruxolitinib 并且服用稳定剂量至少 8 周,但患有 ruxolitinib 无法充分控制的疾病
对于 Arm 3(JAK 抑制剂天真),应考虑以下标准:
- 符合以下所有标准的 MF 确诊患者
- 动态国际预后评分系统 (DIPSS) 风险类别为 2 级或更高
- 血小板计数 ≥ 100 x 10^9/L,无需促血小板生成因子或输血
- MRI/CT 显示脾脏体积≥ 450 cm^3
- 使用骨髓纤维化症状评估表 4.0 版 (MFSAF v4.0) 至少可测量 2 种症状(评分 ≥ 3)或总分 ≥ 10
- 不允许事先使用 JAKi 进行治疗
对于 Arm 4(ET 扩展),应考虑以下标准:
- 确诊为 ET 的患者
- 高危疾病,定义为满足以下至少一项标准:
- 年龄 > 60 岁
- 血小板计数 > 1500 × 10^9/L(在患者患病期间的任何时间点)
- 先前记录的血栓形成、红斑性肢痛或偏头痛
- 既往与 ET 相关的出血
- 糖尿病或高血压需要药物治疗 > 6 个月
使用 MPN SAF 在第 1 周期第 1 天之前的 7 天内有≥2 种症状且平均得分≥3,或者在第 1 周期第 1 天之前的 7 天内平均总得分≥15
- 血小板 > 600 × 10^9/L
- 对 HU 耐药或不耐受
排除标准:
- 目前已知患有人类免疫缺陷病毒 (HIV)、乙型肝炎或丙型肝炎的活动性或慢性感染。
- 心脏功能受损或有临床意义的心脏病
- Child-Pugh B 级或 C 级患者
- 可能显着改变 pelabresib 和/或 ruxolitinib 吸收的胃肠道 (GI) 功能受损或 GI 疾病,包括 CTCAE 等级 >1 的任何未解决的恶心、呕吐或腹泻
- 先前使用 BET 抑制剂治疗。
- 孕妇或哺乳期妇女
- 可能影响参与研究的任何其他并发的严重和/或不受控制的伴随医疗状况
- 不愿或不能遵守本研究方案的患者。
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Phase 1
Patients were enrolled in sequential cohorts (acute leukemia, including acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), and acute undifferentiated or biphenotypic leukemia; chronic myelogenous leukemia (CML) in blast crisis; myelodysplastic syndrome (MDS); myelodysplastic/myeloproliferative neoplasms (MDS/MPN); or myelofibrosis (MF)) and received escalating doses of pelabresib (CPI-0610).
|
CPI-0610 was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)
其他名称:
|
|
实验性的:Phase 2 (Arm 1): Prior JAKi Monotherapy Arm (MF patients treated with pelabresib alone)
|
CPI-0610 was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)
其他名称:
|
|
实验性的:Phase 2 (Arm 2): Prior JAKi Combination Arm
|
CPI-0610 was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)
其他名称:
Ruxolitinib was given orally, twice daily (BID), on a continuous basis for 21 consecutive days of each 21-day cycle.
|
|
实验性的:Phase 2 (Arm 3): JAKi Naïve Combination Arm
Was open to patients with MF who had not previously received a JAKi (pelabresib (CPI-0610) + Ruxolitinib).
|
CPI-0610 was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)
其他名称:
Ruxolitinib was given orally, twice daily (BID), on a continuous basis for 21 consecutive days of each 21-day cycle.
|
|
实验性的:Phase 2 (Arm 4): Essential Thrombocythemia (ET) Monotherapy Arm
Was open to high-risk patients with ET who were resistant or intolerant to hydroxyurea (HU) (pelabresib (CPI-0610) alone).
|
CPI-0610 was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phase 1: Frequency of Dose-limiting Toxicities (DLTs)
大体时间:Up to 21 days
|
A dose-limiting toxicity (DLT) was defined as an adverse event or abnormal laboratory value assessed by the Investigator as unrelated to disease progression, intercurrent illness, or concomitant medications that occurred within the first cycle of treatment (21-day cycle) with pelabresib (CPI-0610), and that met any of the criteria specified in the protocol.
|
Up to 21 days
|
|
Phase 2 (Cohorts 1B, 2B, and Arm 3): Number of Participants With Splenic Response Rate (SVR35) at Week 24
大体时间:Week 24 (Cycle 9 Day 1)
|
Splenic Response Rate (SVR35) at Week 24 was defined as the proportion of participants who demonstrated a reduction of at least 35% in spleen size from baseline, as measured by imaging techniques (MRI or CT), following 24 weeks of treatment.
|
Week 24 (Cycle 9 Day 1)
|
|
Phase 2 (Cohorts 1A and 2A): Number of Participants Enrolled as Transfusion Dependent (TD) With Conversion Rate From Red Blood Cell (RBC) Transfusion Dependence (TD) to Transfusion Independence (TI)
大体时间:Any 12 consecutive weeks (rolling window) during active treatment with pelabresib (CPI-0610), from first dose through treatment discontinuation (up to approximately 8 years for Phase II)
|
Conversion rate was defined as the proportion of participants who converted from transfusion dependence (TD) to transfusion independence (TI).
TD was characterized by receiving an average of at least 2 units of red blood cell (RBC) transfusions per month-amounting to a minimum of 6 units over the 12 weeks prior to enrollment-while TI was defined as the absence of RBC transfusions during any consecutive 12-week period.
|
Any 12 consecutive weeks (rolling window) during active treatment with pelabresib (CPI-0610), from first dose through treatment discontinuation (up to approximately 8 years for Phase II)
|
|
Phase 2 (Arm 4): Number of Participants With Complete Hematological Response (CHR) Rate
大体时间:Over 2 consecutive cycles (rolling window) (1 cycle = 21 days)
|
Complete Hematological Response (CHR) Rate was defined as the proportion of participants who fulfilled the criteria for CHR, based on the modified European LeukemiaNet (ELN) guidelines (Barosi et al 2009): platelet count ≤400 × 10⁹/L, white blood cell (WBC) count ≤10 × 10⁹/L, confirmation of laboratory values after one treatment cycle, and normal spleen size determined by palpation or imaging.
|
Over 2 consecutive cycles (rolling window) (1 cycle = 21 days)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phase 1: Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
大体时间:Up to approximately 6 months
|
The distribution of adverse events was performed through the analysis of frequencies for treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs), based on the monitoring of relevant clinical and laboratory safety parameters.
Treatment-emergent adverse events (TEAEs) in this study were defined as events that began after the first dose of study treatment and continued until 30 days after the last dose, or events that were present prior to the first dose and increased in severity based on preferred term within 30 days following the last dose of pelabresib (CPI-0610).
|
Up to approximately 6 months
|
|
Phase 2 (All Arms): Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria
大体时间:Up to approximately 387 weeks
|
The distribution of adverse events was performed through the analysis of frequencies for treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs), based on the monitoring of relevant clinical and laboratory safety parameters.
Treatment-emergent adverse events (TEAEs) in this study were defined as events that began after the first dose of study treatment and continued until 30 days after the last dose, or events that were present prior to the first dose and increased in severity based on preferred term within 30 days following the last dose of pelabresib (CPI-0610).
|
Up to approximately 387 weeks
|
|
Phase 2 (All Arms): Symptom Improvement From the Patient Global Impression of Change (PGIC) at 12 and 24 Weeks
大体时间:Week 12 (Cycle 5 Day 1), Week 24 weeks (Cycle 9 Day 1)
|
The Patient Global Impression of Change (PGIC) was a single-question, patient-reported assessment that asked individuals to rate their overall change in myeloproliferative neoplasm (MPN) symptoms since starting study treatment.
The participants selected one of seven options, ranging from 'Very much improved' to 'Very much worse'.
'No Change from Baseline' indicated stable symptoms (no improvement or worsening), negative change from Baseline indicated a reduction in symptom severity (improvement), and positive change from Baseline indicated an increase in symptom severity (worsening).
|
Week 12 (Cycle 5 Day 1), Week 24 weeks (Cycle 9 Day 1)
|
|
Phase 2 (Arms 1, 2 and 3): Percent Change From Baseline in Total Symptom Score (TSS) From the Myelofibrosis Symptom Assessment Form (MFSAF v4.0) at 12 and 24 Weeks
大体时间:Baseline, Week 12 (Cycle 5 Day 1), Week 24 (Cycle 9 Day 1)
|
The MFSAF (Myelofibrosis Symptom Assessment Form) was completed by participants every day for 7 days before Day 1 of each treatment cycle, including the 7 days before starting Cycle 1.
It used a 24-hour recall format, asking participants to rate the worst severity of seven symptoms (fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain) during the past 24 hours.
Each symptom was rated on a scale from 0 (Absent) to 10 (Worst Imaginable).
The Total Symptom Score (TSS) was the sum of 7 symptoms (range: 0-70).
'No Change from Baseline' indicated stable symptoms (no improvement or worsening), negative change from Baseline indicated a reduction in symptom severity (improvement), and positive change from Baseline indicated an increase in symptom severity (worsening).
|
Baseline, Week 12 (Cycle 5 Day 1), Week 24 (Cycle 9 Day 1)
|
|
Phase 2 (Arms 1, 2 and 3): Number of Participants Who Achieved a ≥ 50% Reduction in Total Symptom Score (TSS) at 12 and 24 Weeks
大体时间:Week 12 (Cycle 5 Day 1), Week 24 (Cycle 9 Day 1)
|
The proportion of study participants who experienced a reduction of at least 50% in their Total Symptom Score (TSS), as assessed using the Myelofibrosis Symptom Assessment Form (MFSAF v4.0), was evaluated at both 12 and 24 weeks relative to their baseline score.
|
Week 12 (Cycle 5 Day 1), Week 24 (Cycle 9 Day 1)
|
|
Phase 2 (Arms 1, 2 and 3): Number of Participants With Overall Splenic Response Rate (Overall SVR35)
大体时间:Through Phase II completion, an average of 6 years
|
Overall Splenic Response Rate (SVR35) was defined as the proportion of participants who achieved a reduction of at least 35% in spleen size from baseline, as measured by imaging (MRI or CT), at any point between Cycle 1 Day 1 and the End of Study Visit, whichever occurred first.
|
Through Phase II completion, an average of 6 years
|
|
Phase 2 (Arms 1, 2 and 3): Duration of Overall Splenic Response (Overall SVR35)
大体时间:From first onset of splenic response until loss of response, assessed up to approximately 6 years
|
Duration of Overall Splenic Response (overall SVR35) was defined as the time from the first occurrence of a at least 35% reduction in spleen volume from baseline until the earliest of the following: a reduction of less than 35% from baseline combined with an increase of more than 25% from the nadir in spleen volume (as measured by MRI or CT), or death.
The nadir was defined as the lowest spleen volume recorded after baseline and up to the evaluation point at which the initial splenic response was achieved.
|
From first onset of splenic response until loss of response, assessed up to approximately 6 years
|
|
Phase 2 (Cohorts 1A and 2A): Number of Participants With Splenic Response Rate (SVR35) at 12 and 24 Weeks
大体时间:Week 12 (Cycle 5 Day 1), Week 24 weeks (Cycle 9 Day 1)
|
Splenic Response Rate (SVR35) at 12 and 24 weeks was defined as the proportion of participants who achieved a reduction of at least 35% in spleen size from baseline, as determined by imaging (MRI or CT), following 12 and 24 weeks of treatment, respectively.
|
Week 12 (Cycle 5 Day 1), Week 24 weeks (Cycle 9 Day 1)
|
|
Phase 2 (Cohorts 1A and 2A): Duration of Red Blood Cell (RBC) Transfusion Independence (TI) in Participants Who Enroll as Transfusion Dependent (TD)
大体时间:From first onset of TI to earliest onset of loss of TI, assessed up to approximately 6 years
|
Duration of Red Blood Cell (RBC) Transfusion Independence (TI) was defined as the longest continuous period during which participants, having achieved at least 12 weeks of transfusion independence, remained free from RBC transfusions.
|
From first onset of TI to earliest onset of loss of TI, assessed up to approximately 6 years
|
|
Phase 2 (Cohorts 1A and 2A): Early Anemic Response Rate in Participants Who Enroll as Transfusion Dependent (TD)
大体时间:Through Phase II completion, an average of 6 years
|
Early anemic response rate was defined as the proportion of participants who achieved an average increase of at least 1 g/dL in hemoglobin concentration over any rolling 8-week (56-day) period following baseline.
This calculation was performed after applying the 14/3 day rule, which stipulates that hemoglobin measurements must be spaced at least 14 days apart, and that at least 3 such measurements are required within the 8-week window to ensure a reliable average.
Importantly, this increase had to occur without any red blood cell (RBC) transfusions during the treatment period and up to the time of the latest hemoglobin assessment for each patient.
|
Through Phase II completion, an average of 6 years
|
|
Phase 2 (Cohorts 1B, 2B, and Arm 3): Number of Participants With Splenic Response Rate (SVR35) at 12 Weeks
大体时间:Week 12 (Cycle 5 Day 1)
|
Splenic Response Rate (SVR35) at Week 12 was defined as the proportion of participants who achieved a reduction of at least 35% in spleen size from baseline, as measured by imaging (MRI or CT), following 12 weeks of treatment.
|
Week 12 (Cycle 5 Day 1)
|
|
Phase 2 (Cohorts 1B, 2B, and Arm 3): Anemic Response Rate in Participants Who Enroll as Non-transfusion-dependent (Non-TD)
大体时间:Through Phase II completion, an average of 6 years
|
Anemic response was defined as a sustained average increase in hemoglobin concentration of at least 1.5 g/dL over any rolling 12-week (84-day) period following baseline.
This calculation excluded periods involving red blood cell (RBC) transfusions and was performed after applying the 14/3-day rule for valid hemoglobin assessments.
The response had to be maintained through to the most recent available hemoglobin measurement for each patient.
|
Through Phase II completion, an average of 6 years
|
|
Phase 2 (Arm 4): Percentage of Participants Who Achieve a ≥50% Reduction From Baseline in the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Total Score
大体时间:Baseline, 12 weeks (Cycle 5, Day 1), 24 weeks (Cycle 9, Day 1)
|
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) is a patient-reported questionnaire designed to measure symptom burden in participants with myeloproliferative neoplasms (MPNs).
Participants rate the severity of several symptoms (such as fatigue, night sweats, itching, abdominal discomfort, bone pain, early satiety, and others) over the past 24 hours.
Each symptom is scored on a scale from 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be).
The total score is the sum of all individual symptom scores, providing an overall measure of symptom burden.
A 50% reduction in the MPN-SAF total score at 12 or 24 weeks means the patient's overall symptom burden has improved by half compared to their baseline (pre-treatment) score.
|
Baseline, 12 weeks (Cycle 5, Day 1), 24 weeks (Cycle 9, Day 1)
|
|
Phase 2 (Arm 4): Partial Hematological Response Rate (PHR)
大体时间:Over 2 consecutive cycles (rolling window) (1 cycle = 21 days)
|
Partial Hematological Response Rate (PHR) was defined as the proportion of participants who met the following criteria over two consecutive cycles up to the last administration of study treatment:
|
Over 2 consecutive cycles (rolling window) (1 cycle = 21 days)
|
|
Phase 2 (Arm 4): Overall Hematological Response Rate (OHR)
大体时间:Through Phase II completion, an average of 6 years
|
Confirmed Overall Hematological Response (OHR) Rate was defined as the proportion of participants with either a confirmed complete or a partial hematological response at any time.
|
Through Phase II completion, an average of 6 years
|
|
Phase 2 (Arm 4): Duration of Overall Hematological Response Rate (OHR)
大体时间:Through Phase II completion, an average of 6 years
|
Duration of Overall Hematological Response (OHR) Rate was defined as the time from when the overall hematological response was first met until the time at which the overall hematological response was lost, i.e., the criteria for an overall hematological response (CHR or PHR) were not observed or death occurred, whichever came first.
|
Through Phase II completion, an average of 6 years
|
|
Phase 2 (Arm 4): Rate of Hemorrhagic and Thromboembolic (TE) Events
大体时间:Through Phase II completion, an average of 6 years
|
Rate of hemorrhagic and thromboembolic (TE) events was defined as the proportion of participants with hemorrhagic or thromboembolic events throughout the study.
|
Through Phase II completion, an average of 6 years
|
|
Phase 2 (All Arms): Maximum Observed Plasma Concentration (Cmax) of Pelabresib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points. Cmax was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (All Arms): Time to Reach Maximum Concentration (Tmax) of Pelabresib
大体时间:Cycle 1 Day 14 (predose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points. Tmax was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (predose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (All Arms): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Pelabresib
大体时间:Cycle 1 Day 14 (predose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points. Ctrough was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (predose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (All Arms): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Pelabresib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points. AUClast was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (All Arms): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Pelabresib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points. AUC0-8,ss was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (All Arms): Time of Last Measurable Concentration (Tlast) of Pelabresib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points. Tlast was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (Arm 2 - Cohort 2A): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Cmax was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (Arm 2 - Cohort 2A): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Tmax was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (Arm 2 - Cohort 2A): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib
大体时间:Cycle 1 Day 14 (predose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Ctrough was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (predose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (Arm 2 - Cohort 2A): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. AUClast was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (Arm 2 - Cohort 2A): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. AUC0-8,ss was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (Arm 2 - Cohort 2B): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Cmax was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (Arm 2 - Cohort 2B): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Tmax was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (Arm 2 - Cohort 2B): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Ctrough was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (Arm 2 - Cohort 2B): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. AUClast was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (Arm 2 - Cohort 2B): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. AUC0-8,ss was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (Arm 3): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Cmax was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (Arm 3): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Tmax was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (Arm 3): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib
大体时间:Cycle 1 Day 14 (predose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. Ctrough was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (predose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (Arm 3): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. AUClast was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
|
Phase 2 (Arm 3): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib
大体时间:Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points. AUC0-8,ss was listed and summarized using descriptive statistics. |
Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.
|
其他结果措施
结果测量 |
大体时间 |
|---|---|
|
第 2 阶段(第 1、2 和 3 组):评估响应类别率
大体时间:国际工作组的反应率 - 24 周后骨髓增生性肿瘤研究和治疗 (IWG-MRT) 标准
|
国际工作组的反应率 - 24 周后骨髓增生性肿瘤研究和治疗 (IWG-MRT) 标准
|
|
第 2 阶段(第 1、2 和 3 组):评估红细胞输注率和红细胞输注依赖率
大体时间:每个主题月的平均 RBC 单位数,最多 24 周及以上
|
每个主题月的平均 RBC 单位数,最多 24 周及以上
|
合作者和调查者
调查人员
- 研究主任:Novartis Pharmaceuticals、Novartis Pharmaceuticals
出版物和有用的链接
一般刊物
- Stein EM, Fathi AT, Harb WA, Colak G, Fusco A, Mangan JK. Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies. Leuk Lymphoma. 2024 Apr;65(4):503-510. doi: 10.1080/10428194.2023.2300710. Epub 2024 Jan 23.
- Gupta V, Mascarenhas J, Kremyanskaya M, Rampal RK, Talpaz M, Kiladjian JJ, Vannucchi AM, Verstovsek S, Colak G, Dey D, Harrison C. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis. Blood Adv. 2023 Sep 26;7(18):5421-5432. doi: 10.1182/bloodadvances.2023010628.
- Mascarenhas J, Kremyanskaya M, Patriarca A, Palandri F, Devos T, Passamonti F, Rampal RK, Mead AJ, Hobbs G, Scandura JM, Talpaz M, Granacher N, Somervaille TCP, Hoffman R, Wondergem MJ, Salama ME, Colak G, Cui J, Kiladjian JJ, Vannucchi AM, Verstovsek S, Curto-Garcia N, Harrison C, Gupta V. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Myelofibrosis. J Clin Oncol. 2023 Nov 10;41(32):4993-5004. doi: 10.1200/JCO.22.01972. Epub 2023 Mar 7.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 0610-02
- 2018-000579-34 (EudraCT编号)
- CDAK539A12201 (其他标识符:Novartis)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
诺华致力于与合格的外部研究人员共享患者级数据以及来自合格研究的支持临床文件。 这些请求由独立审查小组根据科学价值进行审查和批准。 提供的所有数据均经过匿名处理,以根据适用的法律法规尊重参与试验的患者的隐私。
该试验数据的可用性是根据 www.clinicalstudydatarequest.com 上描述的标准和流程进行的
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.